ALL & acute abdomen: the silent alarm?

By Ana Espino | Published on september 15, 2025 | 2 min read

#Leukemia #ALL #PediatricCancer #Microbiome  


Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children, accounting for a major share of pediatric cancers. Thanks to therapeutic advances, survival rates have markedly improved over recent decades. However, adverse events linked to intensive treatments—particularly acute abdomen—remain a leading cause of non-relapse morbidity and mortality, threatening the trajectory of cure.

This complication, often difficult to diagnose, manifests with nonspecific clinical signs, especially in immunocompromised patients, making early management challenging. Despite its severity, epidemiological and clinical data on acute abdomen in pediatric ALL remain limited—particularly regarding its true incidence, specific risk factors, and prognosis.  

Against this background, the main clinical challenge is to better characterize this entity in order to anticipate its occurrence and adapt monitoring and treatment strategies. The multicenter CCCG-ALL-2015 study was therefore designed to describe the incidence, identify risk factors, and assess the clinical impact of acute abdomen in children with ALL, based on a large nationwide cohort.    

What risk for which abdomen?

Among the 7,640 patients included, 512 children (6.7%) experienced at least one episode of acute abdomen, 57% of which occurred during the induction phase. The most frequent types were acute pancreatitis (4.0%), ileus (1.2%), and acute appendicitis (0.7%), confirmed by clinical, biological, or radiological data. The study analyzed their frequency, timing of onset, and clinical characteristics.  

Univariate and multivariate analyses were then performed to identify independent risk factors and assess their impact on clinical outcomes—particularly the need for intensive care, surgery, and mortality risk.  

Findings confirm that although relatively uncommon, acute abdomen represents a serious complication, primarily affecting patients with high biological and clinical risk. The most severe forms, such as enterorrhagia, were associated with significant mortality, especially in BCR-ABL1–positive patients. The induction phase emerged as the most vulnerable period, combining drug toxicity, profound immunosuppression, and gastrointestinal fragility.  

Despite a low rate of surgical intervention (3.8%), the need for transfer to intensive care in nearly one in five cases (90 episodes) illustrates the potentially life-threatening impact of these complications. These results highlight the importance of early detection, especially in high-risk patients, and the implementation of tailored monitoring protocols from the earliest treatment phases.    

Anticipating better to save better

ALL is the most frequent pediatric leukemia, treated with intensive protocols that may cause severe side effects. Among these, acute abdomen is a serious complication, often difficult to recognize in the context of immunosuppression and potentially life-threatening. The major clinical challenge lies in early detection and rapid management, while data on its incidence, clinical course, and specific risk factors remain incomplete.  

The aim of this study was to describe the clinical characteristics of acute abdomen in pediatric ALL. Results reveal an incidence of 6.7%, with predominance of pancreatitis, ileus, and appendicitis, occurring mainly during induction. Certain profiles—such as patients ≥10 years old, with T-cell phenotype, or classified as high-risk—showed increased vulnerability. Enterorrhagia, though less frequent, carried the highest mortality.  

However, limitations persist, justifying further research. Future studies should include a deeper analysis of infectious causes, better documentation of surgical indications and outcomes, and consideration of recent treatments, particularly immunotherapy. Prospects lie in developing targeted surveillance protocols adapted to identified risk profiles, and preventive strategies. The ultimate goal is to reduce the incidence and severity of acute abdomen, and to support the evolution toward safer, individualized therapeutic protocols for children with ALL.

Read next: ALL: a constantly evolving battle

About the author – Ana Espino
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.